Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737372 | 1.00 | LMNA (0.44) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL15050220 | 1.00 | LMNA (0.44) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1472102 | 0.96 | LMNA (0.44) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL22204407 | 0.89 | KDM4E (0.46) | TSHRKDM4ECNR2 | |
| SCHEMBL6228019 | 0.85 | HRH3 (0.37) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL29221097 | 0.85 | BCHE (0.39) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL23498992 | 0.85 | OXTR (0.41) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL23498743 | 0.85 | OXTR (0.41) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL44458 | 0.82 | ALDH1A1 (0.39) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL15314659 | 0.82 | ALDH1A1 (0.39) | LMNATDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942446-B | Preparation method of pregabalin | 黄冈鲁班药业股份有限公司 | 2021-09-07 | — | — | CN | claimed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12473267-B2 | Process and intermediate for the preparation of oxetan-2-yl-methanamine | ELI LILLY AND COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12234311-B2 | Amphiphilic block copolymer | BYK-CHEMIE GMBH (DE) | 2025-02-25 | — | — | US | disclosed |
| US-20250043165-A1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-12018127-B2 | Additive manufacturing of aromatic thermoplastics from photocurable precursor salts | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018127-B2 | Additive manufacturing of aromatic thermoplastics from photocurable precursor salts | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3580290-B1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG IND OHIO INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | disclosed |
| US-5364614-A | Cascade polymer bound chelating compounds, their chelates and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| EP-0512661-A1 | Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0430863-A2 | Complexe builders bonded to sterwise prepared polymers, their complexes and conjugates, process for their preparation and pharmaceutical agents containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-06-05 | — | — | EP | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
| US-4659721-A | GASTROINTESTINAL DISORDER, HISTAMINE H2-ANTOGONISTS | LUDWIG HEUMANN & CO. GMBH (DE) | 1987-04-21 | — | — | US | disclosed |
| US-4656180-A | HISTAMINE-H2 RECEPTORS; ANTIULCER AGENTS | LUDWIG HEUMANN & CO., GMBH (DE) | 1987-04-07 | — | — | US | disclosed |
| EP-0158789-A1 | Diamine derivatives, process for their preparation and medicines containing these compounds | LUDWIG HEUMANN & CO GMBH (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0154721-A1 | Alcanol derivatives, processes for their preparation and medicines containing these compounds | LUDWIG HEUMANN & CO GMBH (DE) | 1985-09-18 | — | — | EP | disclosed |
| EP-0121972-A2 | N-aryl-alpha-amino-carboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | LMNA 1548/4885TDP1 2918/4885MEN1 3252/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | LMNA 975/4885TDP1 1821/4885MEN1 3741/4885 |
| US-12473267-B2 | Process and intermediate for the preparation of oxetan-2-yl-methanamine | CYP11B2, CYP11B1, MSMO1 | LMNA 801/4885TDP1 3714/4885MEN1 831/4885 |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | BCL9L, BCL2L1, BCL9 | LMNA 964/4885TDP1 1854/4885MEN1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.